Literature DB >> 15254738

The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival.

M T Rubio1, D Ittelet, E Raymond, J Y Blay, J Bernard, S Chouaib.   

Abstract

Mature dendritic cells (mDC) are professional and potent antigen presenting cells required for initiation of primary immune responses. In the present study, we have investigated the effect of vincristine on the T cell allostimulatory potential of human monocyte-derived mDC in allogeneic mixed lymphocyte reaction. Using T lymphocytes as responding cells and mDC as stimulating cells, our data indicate that incubation of DC with vincristine decreased the accessory potency dose dependently and resulted in a subsequent inhibition of T cell proliferative responses. Treatment of mDC with vincristine also led to the alteration of their capacity to produce IL-12 but enhanced their production of IL-10. Using flow cytometry, we demonstrated that vincristine had no effect on mDC phenotype (CD83, CD40, CD86, CD58, CD54) but promoted apoptotic cell death of these cells as revealed by PI and annexin-V. These findings suggest that DC may be potential targets of cytotoxic drugs and point out the possible impairment of the immunocompetence of these cells following chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254738     DOI: 10.3892/ijo.25.2.407

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Authors:  Sonja Obermann; Susanne Petrykowska; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

2.  Differential effects of Paclitaxel on dendritic cell function.

Authors:  Justin John; Mohammed Ismail; Catherine Riley; Jonathan Askham; Richard Morgan; Alan Melcher; Hardev Pandha
Journal:  BMC Immunol       Date:  2010-03-19       Impact factor: 3.615

3.  Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.

Authors:  Jing Wen; Lan Wang; Jie Ren; Emiko Kranz; Shilin Chen; Di Wu; Toshio Kanazawa; Irvin Chen; Yunfeng Lu; Masakazu Kamata
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.